Dr. Reddy’s facility struck by another Form 483

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Aramyan)
(Image: Getty/Aramyan)

Related tags India Fda Form 483

Dr. Reddy’s Bachupally manufacturing plant has received a second Form 483 from the US FDA in the past two years.

The Indian company did not release many details​ regarding the US Food and Drug Administration (FDA)’s findings, only noting that the Hyderabad-based manufacturing plant received 11 observations.

The company stated, “We will address [the observations] comprehensively within the stipulated timeline.”

This is the second time that the formulation manufacturing plant has seen FDA regulatory action at the facility, after it was issued a Form 483 in May 2017​. During the previous inspection that resulted in a Form 483, the agency also found 11 observations, which the company told us, at the time, were ‘mostly procedural’.

The Hyderabad site houses three formulation plants, the most recent inspection relates to ‘plant 3’; the space that also holds the company’s global office, as well as three active pharmaceutical ingredient (API) manufacturing facilities and four R&D sites.

Problems at the site also extended to an API plant, which was issued a Form 483 in March 2018​.

Six months ago, the company sold an API plant​ to the generic joint venture, Therapiva. The company noted the decision to sell was to streamline its business to ‘optimise’ global costs.

Shares in Dr. Reddy’s dipped 4% on the news, dropping from ₹2776 ($39.31) on the release of the news to ₹2663 ($37.71), as of the time of reporting.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more